#1 Clinical Trials Search in Europe

Etripamil

Etripamil is an investigational nasal spray medication being studied for the treatment of certain heart rhythm disorders, primarily paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation (AF). Clinical trials are evaluating its effectiveness, safety, and potential as a self-administered treatment option for patients experiencing episodes of these conditions.

Table of Contents

What is Etripamil?

Etripamil is a new medication being developed as a nasal spray to treat certain heart rhythm disorders. It is also known by its research code name MSP-2017[1]. Etripamil is designed to be a fast-acting treatment that patients can use themselves at home when they experience symptoms of specific heart rhythm problems[2].

What Conditions Does Etripamil Treat?

Etripamil is being studied primarily for two heart rhythm conditions:

  • Paroxysmal Supraventricular Tachycardia (PSVT): This is a condition where the heart suddenly beats very fast for a short period. It’s not usually life-threatening but can cause uncomfortable symptoms[2].
  • Atrial Fibrillation (AF): This is an irregular and often rapid heart rhythm that can lead to blood clots in the heart[3].

How Does Etripamil Work?

Etripamil is a type of medication called a calcium channel blocker. It works by briefly slowing down the electrical signals in certain parts of the heart. This action can help restore a normal heart rhythm in people experiencing PSVT or reduce the heart rate in those with atrial fibrillation[3][2].

How is Etripamil Administered?

Etripamil is designed to be self-administered as a nasal spray. The medication comes in a device called the Aptar Pharma Nasal Spray Bidose System. This allows patients to give themselves the medication quickly when they feel symptoms starting[2]. The typical dose being studied is 70 mg, which is sprayed into the nose. In some studies, patients may take a second dose after 10 minutes if symptoms persist[4].

Clinical Trials and Research

Etripamil is currently being studied in several clinical trials:

  • For PSVT: Large studies like NODE-301, NODE-302, and NODE-303 are testing how well etripamil works and how safe it is when patients use it at home for PSVT episodes[2][5].
  • For Atrial Fibrillation: Studies like ReVeRA-201 and ReVeRA-301 are looking at how etripamil affects heart rate in people with atrial fibrillation[3][4].
  • In Children: The NODE-202 study is testing etripamil in children and teenagers with PSVT[6].
  • In Chinese Patients: Some studies are specifically looking at how etripamil works in Chinese patients[7][8].

Effectiveness of Etripamil

Early studies have shown promising results for etripamil:

  • In PSVT, etripamil has been shown to stop episodes of fast heart rhythm more quickly than a placebo (dummy treatment)[1].
  • For atrial fibrillation, etripamil appears to help lower the heart rate during episodes[3].

However, it’s important to note that research is still ongoing, and more data is needed to fully understand how well etripamil works in different situations.

Safety and Side Effects

Like all medications, etripamil can cause side effects. The most common side effects reported in studies include[9]:

  • Headache
  • Nasal irritation or discomfort
  • Runny nose or congestion
  • Sneezing
  • Throat irritation
  • Watery eyes

Less common but potentially more serious side effects could include changes in blood pressure or other heart rhythm problems. Ongoing studies are carefully monitoring these potential risks[9].

Potential Benefits for Patients

If approved, etripamil could offer several benefits for patients[9]:

  • Quick relief: Patients might be able to stop PSVT episodes quickly at home without needing to go to the hospital.
  • Fewer hospital visits: This could reduce the need for emergency room visits and hospital admissions.
  • Reduced need for other medications: Some patients might be able to stop taking daily medications for preventing PSVT.
  • Alternative to procedures: For some patients, etripamil might provide an alternative to invasive heart procedures.

It’s important to remember that etripamil is still being studied and is not yet approved for general use. Patients should always consult with their healthcare providers about the best treatment options for their specific situation.

Aspect Details
Drug Name Etripamil (also known as MSP-2017)
Administration Nasal spray
Primary Conditions Studied Paroxysmal Supraventricular Tachycardia (PSVT), Atrial Fibrillation (AF)
Typical Dose 70 mg, with some trials evaluating optional second dose
Key Benefits Potential for self-administration, rapid action, reduction in emergency room visits
Common Side Effects Nasal discomfort, congestion, rhinorrhea, headache, increased lacrimation
Trial Phases Phase 1, 2, and 3 studies conducted or ongoing
Special Populations Studies in adults, with some trials focusing on pediatric patients and Chinese subjects
Primary Outcome Measures Time to conversion to sinus rhythm, reduction in ventricular rate

FAQ

  • What is Etripamil and how does it work? Etripamil is an investigational nasal spray medication that belongs to a class of drugs called calcium channel blockers. It works by slowing down electrical signals in the heart to help restore normal heart rhythm in conditions like PSVT and AF.
  • What conditions is Etripamil being studied for? Etripamil is primarily being studied for the treatment of paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation (AF) with rapid ventricular rate.
  • How is Etripamil administered? Etripamil is administered as a nasal spray. In most trials, it is given as a 70 mg dose, with some studies evaluating the option of a second dose if symptoms persist.
  • What are the potential benefits of Etripamil? Etripamil may provide a fast-acting, self-administered treatment option for patients experiencing episodes of PSVT or AF, potentially reducing the need for emergency room visits and allowing for at-home management of these conditions.
  • What are the most common side effects of Etripamil in clinical trials? The most frequently reported side effects include nasal-related symptoms such as nasal discomfort, congestion, and rhinorrhea, as well as headache and increased lacrimation (tear production).

Ongoing Clinical Trials on Etripamil

  • Study of Etripamil Nasal Spray for Children with Paroxysmal Supraventricular Tachycardia (Ages 6-18)

    Recruiting

    1 1
    Investigated drugs:
    Germany The Netherlands Spain

Glossary

  • Paroxysmal Supraventricular Tachycardia (PSVT): A rapid heart rhythm that starts in the upper chambers of the heart and occurs in sudden episodes.
  • Atrial Fibrillation (AF): An irregular and often rapid heart rhythm that can lead to blood clots in the heart.
  • Sinus Rhythm: The normal regular rhythm of the heart set by the natural pacemaker called the sinoatrial node.
  • Electrocardiogram (ECG): A test that records the electrical activity of the heart.
  • Cardiac Monitoring System (CMS): A device used to continuously record heart activity over an extended period.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body.
  • Vagal Maneuver: Physical techniques that can help slow down heart rate in some cases of rapid heartbeat.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Intranasal (IN): Administered through the nose.

References

  1. https://clinicaltrials.gov/study/NCT02296190
  2. https://clinicaltrials.gov/study/NCT03464019
  3. https://clinicaltrials.gov/study/NCT04467905
  4. https://clinicaltrials.gov/study/NCT06716021
  5. https://clinicaltrials.gov/study/NCT03635996
  6. https://clinicaltrials.eu/trial/study-of-etripamil-nasal-spray-for-children-with-paroxysmal-supraventricular-tachycardia-ages-6-18/
  7. https://clinicaltrials.gov/study/NCT05511870
  8. https://clinicaltrials.gov/study/NCT05410860
  9. https://clinicaltrials.gov/study/NCT04952610